Check out the updated version with new FDA drug approvals (As of 04/05/2023*), Available now......
- Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy
- Original Release Date: December 1, 2021
- Expiration Date: April 1, 2026
- Date of Last Review: March 2024
- Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC)
- Estimated time to complete the activity: 30 minutes
- For additional information about the accreditation of this activity, please visit https://partnersed.com
- Computer system hardware/software requirements: SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Course Description
This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.
This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.
Target Audience
The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.
Educational Objectives
Upon completion of this activity, participants should be able to:
|
Basic Mechanisms of Adoptive T Cell Immunotherapy |
|
|---|---|
|
Cellular therapies and Current Clinical Indications |
|
|
Patient Selection for |
|
|
Management of CAR T Cell |
Describe the preparation of CAR T and patient disease management prior to administration.
|
|
Requirements for CAR T Cell Program Development |
|
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Faculty and Disclosure of Conflict of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
|
Presenting Faculty |
Conflicts of Interest |
|
Carl June, MD Richard W. Vague Professor In Immunotherapy, Department of Pathology and Laboratory Medicine Director, Parker Institute for Cancer Immunotherapy Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA |
Novartis: Royalties; AC Immune, Bluesphere Bio, Cellares, Celldex, Cabaletta, Carisma, DeCART, Kiadis, Poseida, Viracta, WIRB-Copernicus Group: Consulting |
|
Certificate Program Task Force |
Conflicts of Interest |
|
Robert L. Ferris, MD, PhD (Chair) UPMC Hillman Cancer Center |
Researcher: Astra-Zeneca/Medimmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro Consultant/Advisor/Speaker: Achilles Therapeutics; Adagene Incorporated, Adaptimmune, Aduro Biotech Inc, Astra-Zeneca/MedImmune; Bicara Therapeutics, Inc, Bristol-Myers Squibb, Brooklyn Immunotherapeutic, Cantenion, Coherus BioSciences, Inc, CureVac, Cytoagents, Eisai Europe Limited, EMD Serono, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd., Federation Bio, Inc, Genmab, Genocea Biosciences, Inc, Hookipa Biotech GmbH, Instill Bio, Inc, Kowa Research Institute, Inc, Lifescience Dynamics Limited, MacroGenics, Inc, MeiraGTx, LLC, Merck, Merus N.V, Mirati Therapeutics, Inc, Mirror Biologics Inc, Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, PPD Development, L.P., Rakuten Medical, Inc, Regeneron, Sanofi, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Tesaro, Vir Biotechnology, Inc, Zymeworks Inc Stocker holder: Novasenta |
|
Umar Farooq, MD University of Iowa |
Researcher: Regeneron Pharmaceuticals; Consultant/Advisor/Speaker: Immpact Bio, Caribou Biosciences, Kite Pharma, MoprhoSys; |
|
Silvia Formenti, MD Weill Cornell Medicine |
Grant/Research Support: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ViewRay, AstraZeneca Consultant/Honoraria: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Nanobiotix |
|
Sigrun Hallmeyer, MD Advocate Medical Group |
Consultant: Cardinal Health |
|
Jose Lutzky, MD, FACP University of Miami Sylvester Cancer Center |
Researcher: BMS Consultant/Advisor/Speaker: Castle, Iovance, Vyriad, Replimune, Takeda, Oncotelic, T-Nanobio, Agenus, Celldex Independent Contractor: BMS, Novartis, Iovance, Replimune, Regeneron, InstilBio, Syntrix, BioNtech, Foghorn, Trisalus, Agenus, Inmatics, Takeda, Dragonfly
|
|
George Weiner, MD University of Iowa |
Researcher: Regeneron, Pfizer |
Joint Accreditation Statement
 |
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PACE’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving PACE permission to use this information/data to report your participation to these Boards JA-PARS.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-24-081-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Instructions for Credit
During the period 12/1/2021 through 4/1/2026 participants must read the learning objectives and faculty disclosures and study the educational activity.
Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.
Satisfactory Completion
Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Media
Internet
Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.